Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies

Saumya Choudhary1,2, Rachana Patel3, Dibyabhaba Pradhan3

  • 1Department of Molecular and Cellular Engineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, 211007 India.

3 Biotech
|February 27, 2020
PubMed

Insights

Psoriasis patients face higher risks for cardiovascular issues like high blood pressure and obesity. This meta-analysis confirms a significant link between psoriasis and increased cardiovascular disease risk factors.

Area of Science:

  • Dermatology and Cardiovascular Medicine
  • Chronic Inflammatory Diseases
  • Epidemiological Research

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • It is associated with various cardiovascular risk factors.
  • Understanding this link is crucial for patient management.

Purpose of the Study:

  • To conduct a meta-analysis assessing the association between psoriasis and cardiovascular risk factors.
  • To identify specific cardiovascular risks prevalent in psoriasis patients.
  • To evaluate regional differences in these associations.

Main Methods:

  • Systematic literature search of MEDLINE/PubMed and Cochrane Library up to June 30, 2018.
  • Inclusion of 26 observational studies with 17,672 psoriasis patients and 66,407 controls.
  • Meta-analysis and subgroup analyses by continent.

Main Results:

  • Psoriasis patients showed significantly increased risks for systolic blood pressure, diastolic blood pressure, abdominal obesity, and triglycerides.
  • Subgroup analysis indicated higher cardiovascular risk factors in Middle Eastern psoriasis patients.
  • European psoriasis patients exhibited increased LDL-C and waist circumference.

Conclusions:

  • Psoriasis is significantly associated with an increased incidence of major adverse cardiovascular events.
  • Hypertension is a highly associative condition in psoriasis patients.
  • Further validation in diverse regional cohorts is recommended.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...